

Future Medicine & Expert Reviews enjoy growth of Impact Factors

PRESS RELEASE FROM FUTURE SCIENCE GROUP

June 2010

Contact: Craig Canham
Corporate Public Relations, Future Science Group
Tel: +44 (0) 20 8371 6092
Email: c.canham@futuremedicine.com

Future Science Group titles enjoy continued growth in Impact Factors

Future Science Group (FSG) announced highlights of its latest journal Impact Factor results, with impressive results across its imprints **Future Medicine** and **Expert Reviews**, following the recent publication of the new Impact Factors in the 2009 Journal Citation Report (JCR) by Thomson Reuters. Impact Factors, calculated by Thomson Reuters indicate the number of times a published article has been cited during the course of a year – providing an indication on how much of an ‘impact’ a journals content is making on its research audience.

Together with the increase in impact factors across the **Future Medicine** and **Expert Reviews** portfolios, most journals also see an improvement in their ranking within specific categories. The star performers were *Expert Review of Vaccines* with an impressive increase to 4.214 from 2.979, and *Future Microbiology*, with an increase to 2.875 from 1.976 last year.

Launched in 2002 and 2006 respectively, *Expert Review of Vaccines* and *Future Microbiology* were selected for coverage in ISI® services and Medline at the earliest opportunity. *Future Microbiology* provides an interdisciplinary forum for all scientists working in the field today, bringing together the diverse subject areas of bacteriology, mycology, parasitology and virology. *Expert Review of Vaccines* reviews the clinical effectiveness of new vaccines, with coverage including vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.

The Editorial Advisory panel for both titles were delighted at the jump in Impact factor, **Andrew J Pollard** - Professor of Pediatric Infection & Immunity, Director of the Oxford Vaccine Group, University of Oxford, UK – said:

“Expert Review of Vaccines is the authoritative platform for keeping abreast of knowledge and development in the field of vaccinology – it is great news that our journal is gaining recognition and an increased readership can only make us proud.” and **SH Kaufmann**, Max-Planck-Institute for Infection Biology, Germany, commented:

“Future Microbiology provides cutting edge perspective on the novel concepts and technological opportunities in the fight against microbial diseases in the post-genomic era. A worthy winner, and brings with it a sense of responsibility to maintain the highest standards of scientific quality generated in our laboratories and the need to contribute to clinical practice should be the main motivating forces from now on.”

The improved 2009 Impact Factors are testament to the fact that the **Future Medicine & Expert Review** journals are of high quality and widely read, and highly respected by researchers. The journals are now becoming a high priority for authors wishing to submit their important research findings and scientific opinions.

Editorial Director of FSG, Elisa Manzotti said,

*"...the overall trend is up, and it is fantastic to see **Expert Reviews** and **Future Medicine** titles enjoying a year on year increase. I'm also delighted to note that Expert Review of Vaccines took an impressive leap in one year, which is a huge credit to the Editorial Advisory Board and in-house team, together with the many authors and referees who are committed to the title, and made the title such an unqualified success."*

Five titles in the **Expert Review** series and seven **Future Medicine** publications had increased Impact Factors. In addition, *Expert Review of Anti-infective Therapy* was awarded its first Impact Factor of 2.857 – an exciting development in light of the vast amount of research literature published each year.

Dr David Hughes, Publisher for the **Future science Group**, said,

*"The **Future Science Group** portfolio brings a new and fresh approach to learned publishing, often addressing areas of science and medicine that are, as yet, in their infancy. It is very exciting, therefore, to see these titles becoming so well established in the journals firmament."*

The **Future Science Group** has an expanding portfolio of innovative titles, with 2010 launches including *Therapeutic Delivery, Pain Management, Diabetes Management, Neurodegenerative Disease Management, Neuropsychiatry* and *Carbon Management*. Full information on all titles can be found at www.expert-reviews.com, www.futuremedicine.com and www.future-science.com. Free institutional site license and personal online trials are available upon request.

-- ENDS --

For further information please contact:

Craig Canham, Corporate Public Relations, **Future Science Group**

T: +44 (0) 20 8371 6092 F: +44 (0) 20 8371 6099 E: c.canham@futuremedicine.com

NOTES FOR EDITORS

About *Expert Review of Anti-infective Therapy*

ISSN: 1478-7210; Volume: Number 9 (2011); Frequency: 12 issues per year

Description

Expert Review of Anti-infective Therapy provides critical analysis and commentary on the latest approaches to the management of bacterial, viral, fungal and parasitic infectious diseases as those involved in the research and development of anti-infective therapies address these challenges.

Issues addressed include:

- Effectiveness of conventional antibiotic agents
- The HIV/AIDS epidemic in the developing world
- Hospital-borne infections causing the closure of key health facilities
- Increasing prevalence of viral infections
- Concerns over the use of infectious agents as weapons of bioterrorism

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Scopus

About *Expert Review of Vaccines*

ISSN: 1476-0584; Volume: Number 10 (2011); Frequency: 12 issues per year

Description

The vaccine field has been transformed by the technological advances of the past decade; however there remain many challenges in the delivery of cost-effective, safe vaccines. *Expert Review of Vaccines* provides structured, informed commentary on the development and application of new vaccines and vaccine technologies.

Coverage includes:

- Advanced vaccine technologies and delivery systems
- Vaccine adjuvants
- Prophylactic and therapeutic vaccines
- Profiles of vaccine products and their clinical efficacy
- Prospects for new vaccine targets and applications
- Vaccines in bioterrorism

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Scopus

About: *Future Microbiology*

ISSN: 1746-0913, Volume: Number 6 (2011), Frequency: 12 issues per year

Description

Future Microbiology provides an interdisciplinary forum for all scientists working in the field today, bringing together the diverse subject areas of bacteriology, mycology, parasitology and virology.

Future Microbiology covers key areas, such as:

- The molecular basis of microbial diseases and microbe – host interactions
- Overviews highlighting optimal therapeutic and diagnostic approaches
- The use of microbes in the treatment of disease and genetic engineering
- Summaries evaluating newly approved antimicrobial agents
- Pharmacoeconomics and cost-benefit issues in microbiology
- New and re-emerging microbes impacting human health
- Microbial genome research and the implications for higher organisms

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, CAPCAS, EMBiology, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus

Journal Citation Report (Thomson Reuters, 2010)

All Impact Factors are taken from the 2009 *Journal Citation Report*, Science Edition (Thomson Reuters, 2010). Thomson Reuters provide information about how Impact Factors are calculated here: scientific.thomson.com/free/essays/journalcitationreports/impactfactor/ and more detail on the *Journal Citation Report* here: scientific.thomsonreuters.com/products/jcr/

Journal Citation Reports® (JCR) offers a systematic, objective means to critically evaluate the world's leading journals, with quantifiable, statistical information based on citation data. By compiling articles' cited references, JCR Web helps to measure research influence and impact at the journal and category levels, and shows the relationship between citing and cited journals.

The impact factors, which are calculated by ISI, look at citations in 2008 of articles published in the journals in the period 2006-2007.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, **Thomson Reuters** employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com

About Future Science Group

Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. Through its imprints, **Expert-Reviews**, **Future Medicine**, and **Future Science**, the **Future Science Group** provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. For more information please access www.expert-reviews.com, www.futuremedicine.com, www.future-science.com and www.future-science-group.com